TransCode Therapeutics, Inc., a biopharmaceutical company, has announced its plans to hold the 2024 annual meeting of stockholders on June 13, 2024. The company, listed on the Nasdaq Capital Market under the trading symbol RNAZ, has set April 22, 2024, as the record date for stockholders entitled to notice and voting rights at the upcoming annual meeting. This date also marks the deadline for stockholders to submit proposals for inclusion in the proxy materials, with a cut-off time at the close of business on April 25, 2024. Proposals received after this date will not be considered for inclusion in the proxy materials nor at the annual meeting. The announcement complies with SEC regulations, including Rule 14a-8 of the Exchange Act, and follows Delaware law. The location and...Show More

TransCode Therapeutics, Inc., a biopharmaceutical company, has announced its plans to hold the 2024 annual meeting of stockholders on June 13, 2024. The company, listed on the Nasdaq Capital Market under the trading symbol RNAZ, has set April 22, 2024, as the record date for stockholders entitled to notice and voting rights at the upcoming annual meeting. This date also marks the deadline for stockholders to submit proposals for inclusion in the proxy materials, with a cut-off time at the close of business on April 25, 2024. Proposals received after this date will not be considered for inclusion in the proxy materials nor at the annual meeting. The announcement complies with SEC regulations, including Rule 14a-8 of the Exchange Act, and follows Delaware law. The location and time of the meeting will be detailed in the definitive proxy statement. TransCode Therapeutics, which identifies as an emerging growth company, has also aligned with the SEC's universal proxy rules, requiring stockholders who wish to solicit proxies for director nominees other than the company's nominees to provide written notice by the April 25 deadline.